Poster
101
(#101) Healthcare Resource Utilization and Cost Burden in Schizophrenia Patients With and Without Evidence of Tardive Dyskinesia
Psych Congress 2025
Abstract: Background: Antipsychotics (APs) can cause tardive dyskinesia (TD) and can have low adherence, leading to poor clinical outcomes. We analyzed real-world AP use, healthcare resource utilization (HCRU), and economic burden of TD among patients with schizophrenia (SCZ).
Methods: PharMetrics Plus (PMP, 01/2009-9/2023) and MarketScan Medicaid (MM, 01/2014-12/2022) claims database retrospective analyses included patients aged ≥18 years with SCZ and ≥12 months of continuous enrollment before and after the earliest diagnosis (index date). Patients with and without TD evidence (diagnosis or VMAT-2 inhibitor use) were propensity matched by age, gender, race (MM only), Elixhauser comorbidity index, and index year. Data were compared by TD status during the 1-year post-index date.
Results: In PMP and MM, 2.2% and 2.6% of the SCZ cohorts (N=43,411 and N=47,796), respectively, and 16.7% of both matched cohorts had TD evidence. AP use was higher for TD versus no TD groups (PMP: first-generation [FGAs]; 27.9%/15.8%; second-generation [SGAs]; 85.8%/72.9%; MM: FGAs; 30.7%/15.1%; SGAs; 97.4%/83.7%). In MM, the TD versus no TD group had higher treatment persistence rates for any AP and oral/long-acting injectable (LAI) SGAs, but lower adherence rates for oral/LAI FGAs; PMP had similar trends, except the TD group had higher and similar adherence rates for oral FGAs and SGAs, respectively. The TD group had higher total all-cause and psychiatric-related HCRU and health-related costs in both databases.
Discussion: Overall AP use and FGA/SGA adherence differences were observed by TD status; greater HCRU/economic burden in the TD group underscores unmet needs in SCZ with TD.
Short Description: In this retrospective analysis of individuals with schizophrenia from the PharMetrics Plus (01/2009 to 9/2023) and MarketScan Medicaid (01/2014 to 12/2022) claims databases, propensity matched patients with tardive dyskinesia had differences in antipsychotic use and adherence, and were more likely to have greater healthcare resource utilization and associated costs relative to patients without tardive dyskinesia. This underscores the need for increased attention to patients with schizophrenia who experience tardive dyskinesia.
Name of Sponsoring Organization(s): Bristol Myers Squibb
Methods: PharMetrics Plus (PMP, 01/2009-9/2023) and MarketScan Medicaid (MM, 01/2014-12/2022) claims database retrospective analyses included patients aged ≥18 years with SCZ and ≥12 months of continuous enrollment before and after the earliest diagnosis (index date). Patients with and without TD evidence (diagnosis or VMAT-2 inhibitor use) were propensity matched by age, gender, race (MM only), Elixhauser comorbidity index, and index year. Data were compared by TD status during the 1-year post-index date.
Results: In PMP and MM, 2.2% and 2.6% of the SCZ cohorts (N=43,411 and N=47,796), respectively, and 16.7% of both matched cohorts had TD evidence. AP use was higher for TD versus no TD groups (PMP: first-generation [FGAs]; 27.9%/15.8%; second-generation [SGAs]; 85.8%/72.9%; MM: FGAs; 30.7%/15.1%; SGAs; 97.4%/83.7%). In MM, the TD versus no TD group had higher treatment persistence rates for any AP and oral/long-acting injectable (LAI) SGAs, but lower adherence rates for oral/LAI FGAs; PMP had similar trends, except the TD group had higher and similar adherence rates for oral FGAs and SGAs, respectively. The TD group had higher total all-cause and psychiatric-related HCRU and health-related costs in both databases.
Discussion: Overall AP use and FGA/SGA adherence differences were observed by TD status; greater HCRU/economic burden in the TD group underscores unmet needs in SCZ with TD.
Short Description: In this retrospective analysis of individuals with schizophrenia from the PharMetrics Plus (01/2009 to 9/2023) and MarketScan Medicaid (01/2014 to 12/2022) claims databases, propensity matched patients with tardive dyskinesia had differences in antipsychotic use and adherence, and were more likely to have greater healthcare resource utilization and associated costs relative to patients without tardive dyskinesia. This underscores the need for increased attention to patients with schizophrenia who experience tardive dyskinesia.
Name of Sponsoring Organization(s): Bristol Myers Squibb
